COLORADO SPRINGS, Colo.,
July 24, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing
in cannabis formulation-based drug development and related
consulting is pleased to announce the appointment of Dr.
Roscoe M. Moore, Jr., formerly the
US Assistant Surgeon General, for a second term on the scientific
advisory board and as a special Senior Advisor to the Company.
Among other contributions, Dr. Moore will be leading the Cannabis
Science initiative in Africa.
"We are delighted that Dr. Moore has agreed to continue to share
his breadth of knowledge and experience with Cannabis Science
executives and scientific advisors on epidemiology, government
regulation, and international challenges in delivery of disease
treatment", stated Dorothy H. Bray,
Ph.D., Director, President and CEO, Cannabis Science, Inc.
About Roscoe M. Moore Jr.,
D.V.M., M.P.H., Ph.D., Senior Advisor to Cannabis Science and
Senior Member of the Company's Scientific Advisory Board
Dr. Moore brings to the Company substantial experience and
leadership through his government service that includes
responsibilities as former Assistant United States Surgeon General
and Rear Admiral in the USPHS.
Dr. Moore served as the chief epidemiologist with the Centers of
Devices and Radiological Health in the US Food and Drug
Administration (FDA), along with the positions he held in the US
Public Health Service (USPHS), and most recently, with the Office
of the US Secretary of Health and Human Services (HHS).
Dr. Moore was named a Senior Fellow at the Potomac Institute in
June 2003. He is currently the CEO
and Vice Chairman of the Global Flu Consortium.
Dr. Moore was the top-ranking veterinarian in all of the
Uniformed Services, and served as the Associate Director for
Development Support and African Affairs for HHS. In this
capacity, Dr. Moore was the principal liaison between HHS and
ministries of health for 53 countries in Africa. He also held
positions at the National Institutes of Health (NIH), the Centers
for Disease Control (CDC).
Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology
from the University of Michigan, a
Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; and an honorary D.Sc. degree
from Tuskegee University in recognition
of his distinguished public health career. He has written or
co-authored over 100 publications covering a broad range of public
health issues. For a full biography of Dr. Moore, please see
http://phrockwood.com/adobePDFs/Biography.pdf.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment of illnesses caused by infections as well as for
age-related ailments. The Company's initial focus is on skin
cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, Director,
President & CEO
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, Director & CFO
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.